New drug cocktail shows promise against deadly thyroid cancer before surgery

NCT ID NCT04675710

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help people with a rare and aggressive thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF V600E). The goal is to shrink the tumor enough so that surgeons can remove it completely. The trial includes 30 participants and aims to improve survival and surgical success rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland squamous cell carcinoma thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID GLAND ANAPLASTIC CARCINOMA THYROID GLAND SQUAMOUS CELL CARCINOMA

Contacts and locations

Show contact details

Locations

Cleveland Clinic Taussig Cancer Institute

Cleveland, Ohio, 44195, United States
Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, 84112, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic

Rochester, Minnesota, 55901, United States
Stanford School of Medicine

Stanford, California, 94304, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.